SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-276286
Filing Date
2019-10-28
Accepted
2019-10-28 16:55:49
Documents
14
Period of Report
2019-10-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d825479d8k.htm   iXBRL 8-K 32200
2 EX-99.1 d825479dex991.htm EX-99.1 5420
6 GRAPHIC g825479g1028223327617.jpg GRAPHIC 4534
  Complete submission text file 0001193125-19-276286.txt   171745

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vnda-20191022.xsd EX-101.SCH 3108
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20191022_lab.xml EX-101.LAB 18141
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20191022_pre.xml EX-101.PRE 11434
11 EXTRACTED XBRL INSTANCE DOCUMENT d825479d8k_htm.xml XML 3372
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 191173660
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences